Literature DB >> 27020038

How far have we come in terms of estrogens in breast cancer? [Review].

Keely May McNamara1, Fouzia Guestini, Minako Sakurai, Kyoko Kikuchi, Hironobu Sasano.   

Abstract

Major advances in breast cancer treatment have almost always been linked to the actions of estrogen. Therefore, this review focused on estrogen actions in the breast, particularly the developments of the past 20 years, the present understanding of disease biology and possible future developments. Within these areas have focused on what is known about the underlying molecular biology and in particular integration of the bioinformatics revolution of the last 15 years with other facets of research. In addition, there will be an emphasis on the understanding brought about by a greater appreciation for the intracrinology of the breast.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27020038     DOI: 10.1507/endocrj.EJ16-0022

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.

Authors:  Keely M McNamara; Fouzia Guestini; Torill Sauer; Joel Touma; Ida Rashida Bukholm; Jonas C Lindstrøm; Hironobu Sasano; Jürgen Geisler
Journal:  Br J Cancer       Date:  2018-03-22       Impact factor: 7.640

2.  Cancer types with high numbers of driver events are largely preventable.

Authors:  Aleksey V Belikov; Sergey V Leonov
Journal:  PeerJ       Date:  2022-01-05       Impact factor: 2.984

3.  Estrogen induces the expression of EBV lytic protein ZEBRA, a marker of poor prognosis in nasopharyngeal carcinoma.

Authors:  Hirotomo Dochi; Satoru Kondo; Takayuki Murata; Masaki Fukuyo; Asuka Nanbo; Kousho Wakae; Wen-Ping Jiang; Toshihide Hamabe-Horiike; Mariko Tanaka; Takumi Nishiuchi; Harue Mizokami; Makiko Moriyama-Kita; Eiji Kobayashi; Nobuyuki Hirai; Takeshi Komori; Takayoshi Ueno; Yosuke Nakanishi; Miyako Hatano; Kazuhira Endo; Hisashi Sugimoto; Naohiro Wakisaka; Shin-Hun Juang; Masamichi Muramatsu; Atsushi Kaneda; Tomokazu Yoshizaki
Journal:  Cancer Sci       Date:  2022-06-27       Impact factor: 6.518

4.  Breast Cancer Patients Have Greatly Benefited from the Progress in Molecular Oncology.

Authors:  Bernd L Groner; Nancy E Hynes
Journal:  PLoS Biol       Date:  2016-09-29       Impact factor: 8.029

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.